Cutaneous Lymphoma Clinical Trials

December 16, 2016 | by City of Hope

While treatment therapies exist for CTCL (MF/SS) and other cutaneous lymphomas, the most prevalent therapies have not yet offered consistent and sustained response or cure. Our multidisciplinary team continues to provide leadership in research and in developing therapies to advance a cure."
Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program and Assistant Professor, Dermatology/Dermatopathology

For more information on a specific clinical trial, please call 626-218-1133. For a full listing of clinical trials, visit clinicaltrials.coh.org
 

  Cutaneous Lymphoma
 
Christiane Querfeld, M.D., Ph.D.
Learn more about
Dr. Querfeld
Christiane Querfeld, M.D., Ph.D.
IRB 15157: A PROspective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor®.

PHASE I
IRB 16273: A Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides.

PHASE I
IRB 15270: A Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type.

PHASE III
IRB 15122: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma.
 
 
Jasmine Zain, M.D.
Learn more about
Dr. Zain
Jasmine Zain, M.D.
Phase I
IRB 15165: A Study Evaluating Safety, Tolerability, and Pharmakinetics of Escalating Doses or AGS67E Given as Monotherapy in Subjects with Refractory or Relapsed Lymphoid Malignancies.

Phase I
IRB 14349: A Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients with Mature T-Cell Non-Hodgkin Lymphoma: the aTAC-BEAM Regimen.

Phase I / Ib
IRB 15428: A Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual P13K Delta/Gamma Inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma.

Phase I / IIa
IRB 16257: An Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors of Lymphomas Expressing Wild-Type p53 Protein.

Phase II
IRB 16042: A Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL).

Phase II
IRB 14321: A Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL).

Phase II
IRB 14290: A Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL

Phase II
IRB 15332: A Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL).

Phase III
IRB 14338: A Randomized, Double-Blind, Placebo-Controlled Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas.
 
                                                           

 

Categories : Clinical Trials

You may also be interested in

Back To Top

Search Blogs